Related Experiment Video
Updated: Aug 7, 2026
19:16
The Importance of Correct Protein Concentration for Kinetics and Affinity Determination in Structure-function Analysis
Published on: March 17, 2010
Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin
A Sahu1, A M Soulika, D Morikis
1Protein Chemistry Laboratory, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Journal of Immunology (Baltimore, Md. : 1950)
|August 18, 2000
Summary
Compstatin peptide inhibits complement activation by binding to complement component C3. N-acetylation enhances its stability against enzymatic degradation, making acetylated Compstatin a promising therapeutic candidate.
Area of Science:
- Biochemistry
- Immunology
- Medicinal Chemistry
Background:
- Compstatin is a 13-residue cyclic peptide identified for its ability to bind complement component C3 and inhibit complement activation.
- Understanding the binding kinetics, structure-activity relationship, and biotransformation of Compstatin is crucial for its therapeutic development.
Purpose of the Study:
- To characterize the binding kinetics and affinity of Compstatin to complement component C3 and its fragments.
- To elucidate the structure-activity relationship of Compstatin through analog synthesis and analysis.
- To investigate the biotransformation pathways of Compstatin in human blood and explore strategies for enhancing its stability.
Main Methods:
- Surface plasmon resonance (SPR) was employed to analyze the binding kinetics and affinities of Compstatin to C3, C3b, and C3c.
- Synthesis and analysis of Compstatin analogs were performed to determine structure-activity relationships.
- In vitro studies in human blood were conducted to investigate Compstatin's biotransformation.
Main Results:
- Compstatin binds to native C3, C3b, and C3c, but not C3d. Binding to C3b and C3c showed significantly lower affinities compared to native C3.
- The 11-membered ring structure and specific residues within the type I beta-turn segment are critical for Compstatin's activity and interaction with C3.
- The primary biotransformation pathway involves the removal of Ile1, which can be prevented by N-acetylation, leading to enhanced peptide stability.
Conclusions:
- Acetylated Compstatin exhibits increased stability against enzymatic degradation, suggesting its potential as a therapeutic agent.
- The type I beta-turn segment is essential for maintaining Compstatin's conformational stability and its interaction with complement component C3.
- These findings provide valuable insights into the molecular mechanisms underlying Compstatin's function and stability, paving the way for optimized drug design.
More Related Videos
Related Concept Videos
02:18The Equilibrium Binding Constant and Binding Strength
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
01:29Drug Distribution: Plasma Protein Binding
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
01:27Complement System
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
01:16Protein-Drug Binding: Mechanism and Kinetics
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
01:22Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .